TY - JOUR
T1 - Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery
T2 - results of a multicenter, randomized, prospective, phase II clinical trial
AU - Maehara, Yoshihiko
AU - Shirabe, Ken
AU - Kohnoe, Shunji
AU - Emi, Yasunori
AU - Oki, Eiji
AU - Kakeji, Yoshihiro
AU - Baba, Hideo
AU - Ikeda, Masataka
AU - Kobayashi, Michiya
AU - Takayama, Tadatoshi
AU - Natsugoe, Shoji
AU - Haraguchi, Masashi
AU - Yoshida, Kazuhiro
AU - Terashima, Masanori
AU - Sasako, Mitsuru
AU - Yamaue, Hiroki
AU - Kokudo, Norihiro
AU - Uesaka, Katsuhiko
AU - Uemoto, Shinji
AU - Kosuge, Tomoo
AU - Sawa, Yoshiki
AU - Shimada, Mitsuo
AU - Doki, Yuichiro
AU - Yamamoto, Masakazu
AU - Taketomi, Akinobu
AU - Takeuchi, Masahiro
AU - Akazawa, Kouhei
AU - Yamanaka, Takeharu
AU - Shimokawa, Mototsugu
N1 - Funding Information:
This work was supported by a grant from the Japan Surgical Society Clinical Investigation Project Award and a Health Labour Science Research Grant (Rinsho-Ippan-006). The sponsor of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication.
Publisher Copyright:
© 2017, Springer Japan.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Background: The use of absorbable sutures in wound closure has been shown to reduce the incidence of surgical site infection (SSI); however, there is no evidence that the intra-abdominal use of absorbable rather than silk sutures reduces the incidence of SSI after gastrointestinal surgery. We report the findings of a phase II trial, designed to evaluate the impact of the intra-abdominal use of absorbable sutures on the incidence of SSI. Methods: At 19 Japanese hospitals, 1147 patients undergoing elective gastrectomy, colorectal surgery, hepatectomy, or pancreaticoduodenectomy (PD) were randomly assigned to absorbable or silk intra-abdominal suture groups. The primary efficacy endpoint was the incidence of SSI. The secondary efficacy endpoints were the locations of SSI, time to resolution of SSI, length of hospital stay, and the incidence of bile leakage in hepatectomy and pancreatic fistula. Results: The incidence of SSI was 11.3%, 15.5%, 11.3%, and 36.9% after gastrectomy, colorectal surgery, hepatectomy, and PD, respectively. The incidence of SSI was higher in the absorbable suture group than in the silk suture group for all the surgical procedures, but the difference was not significant. Conclusion: The intra-abdominal use of absorbable sutures did not have enough of an effect on the reduction of SSI in this phase II trial to justify the planning of a large-scale phase III trial.
AB - Background: The use of absorbable sutures in wound closure has been shown to reduce the incidence of surgical site infection (SSI); however, there is no evidence that the intra-abdominal use of absorbable rather than silk sutures reduces the incidence of SSI after gastrointestinal surgery. We report the findings of a phase II trial, designed to evaluate the impact of the intra-abdominal use of absorbable sutures on the incidence of SSI. Methods: At 19 Japanese hospitals, 1147 patients undergoing elective gastrectomy, colorectal surgery, hepatectomy, or pancreaticoduodenectomy (PD) were randomly assigned to absorbable or silk intra-abdominal suture groups. The primary efficacy endpoint was the incidence of SSI. The secondary efficacy endpoints were the locations of SSI, time to resolution of SSI, length of hospital stay, and the incidence of bile leakage in hepatectomy and pancreatic fistula. Results: The incidence of SSI was 11.3%, 15.5%, 11.3%, and 36.9% after gastrectomy, colorectal surgery, hepatectomy, and PD, respectively. The incidence of SSI was higher in the absorbable suture group than in the silk suture group for all the surgical procedures, but the difference was not significant. Conclusion: The intra-abdominal use of absorbable sutures did not have enough of an effect on the reduction of SSI in this phase II trial to justify the planning of a large-scale phase III trial.
UR - http://www.scopus.com/inward/record.url?scp=85013657530&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013657530&partnerID=8YFLogxK
U2 - 10.1007/s00595-017-1480-3
DO - 10.1007/s00595-017-1480-3
M3 - Review article
C2 - 28233105
AN - SCOPUS:85013657530
SN - 0941-1291
VL - 47
SP - 1060
EP - 1071
JO - Surgery Today
JF - Surgery Today
IS - 9
ER -